Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Delayed Quote USD

Apogee Therapeutics, Inc. (APGE)

Compare
35.61
-1.75
(-4.68%)
At close: April 1 at 4:00:00 PM EDT
35.61
0.00
(0.00%)
After hours: April 1 at 5:17:50 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for APGE

Recent News: APGE

View More
Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025?

Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025?
Insider Monkey 6 days ago
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Benzinga 29 days ago
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
GlobeNewswire 29 days ago
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
GlobeNewswire 29 days ago
Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?

Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?
Insider Monkey last month
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
GlobeNewswire last month
Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewswire last month
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
GlobeNewswire last month
Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025

Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025
Insider Monkey last month
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
GlobeNewswire 2 months ago
This Apogee Therapeutics Insider Increased Their Holding In The Last Year

This Apogee Therapeutics Insider Increased Their Holding In The Last Year
Simply Wall St. 3 months ago
View More

Related Tickers

SYRE Spyre Therapeutics, Inc.
15.30
-5.21%
 
ACLX Arcellx, Inc.
60.70
-7.47%
 
ORKA Oruka Therapeutics, Inc.
9.56
-6.82%
 
CRNX Crinetics Pharmaceuticals, Inc.
30.62
-8.71%
 
MRUS Merus N.V.
39.60
-5.92%
 
NUVL Nuvalent, Inc.
68.00
-4.12%
 
MLTX MoonLake Immunotherapeutics
36.35
-6.96%
 
EWTX Edgewise Therapeutics, Inc.
20.13
-8.50%
 
CNTA Centessa Pharmaceuticals plc
13.23
-8.00%
 
IMVT Immunovant, Inc.
15.20
-11.06%